NewEdge Wealth LLC Acquires New Position in Edwards Lifesciences Corporation $EW

NewEdge Wealth LLC acquired a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 6,703 shares of the medical research company’s stock, valued at approximately $571,000.

Other large investors also recently bought and sold shares of the company. Brighton Jones LLC purchased a new stake in shares of Edwards Lifesciences in the 4th quarter valued at approximately $266,000. NewEdge Advisors LLC grew its stake in shares of Edwards Lifesciences by 8.1% in the 2nd quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock valued at $2,787,000 after buying an additional 2,665 shares during the period. Sei Investments Co. grew its stake in shares of Edwards Lifesciences by 16.7% in the 2nd quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock valued at $32,285,000 after buying an additional 58,988 shares during the period. Squarepoint Ops LLC grew its stake in shares of Edwards Lifesciences by 277.7% in the 2nd quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock valued at $5,417,000 after buying an additional 50,924 shares during the period. Finally, Treasurer of the State of North Carolina grew its stake in shares of Edwards Lifesciences by 0.4% in the 2nd quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock valued at $21,028,000 after buying an additional 1,065 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on EW shares. BTIG Research increased their price target on shares of Edwards Lifesciences from $98.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, April 24th. Robert W. Baird increased their price target on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research note on Friday, April 24th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Monday, April 20th. Stifel Nicolaus set a $110.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Tuesday, January 20th. Finally, Truist Financial set a $90.00 price target on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $95.65.

Insiders Place Their Bets

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the sale, the chief financial officer directly owned 39,699 shares in the company, valued at $3,177,507.96. This represents a 24.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $83.98, for a total transaction of $85,575.62. Following the sale, the vice president owned 33,682 shares in the company, valued at approximately $2,828,614.36. This trade represents a 2.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 88,096 shares of company stock worth $7,288,799 in the last ninety days. 0.31% of the stock is owned by corporate insiders.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $81.34 on Friday. The firm’s 50 day moving average price is $81.50 and its 200-day moving average price is $82.86. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $87.89. The firm has a market cap of $46.84 billion, a P/E ratio of 43.27, a P/E/G ratio of 2.04 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. The company had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm’s quarterly revenue was up 16.7% on a year-over-year basis. During the same period in the prior year, the business earned $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities research analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.